Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)
Study sponsor: Mirum Pharmaceuticals, Inc. · MIRM
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2027-10Estimated
Enrollment · participants60Estimated
Source updated2026-09-29Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.